Health Rosetta Group

Dave Chase, the firm's co-founder, leads investment decisions. Chase previously founded Avado, a health-tech company acquired by WebMD, and spent years building the nonprofit Health Rosetta ecosystem before launching the investment vehicle. The firm has not publicly disclosed a separate investment committee or additional managing partners.

The two entities share a common founder in Dave Chase and a common intellectual framework — the 42-component Health Rosetta blueprint for high-performing health plans. The nonprofit certifies employer health plans and advisors; the investment firm uses that certification framework to evaluate and operate healthcare-services acquisitions. They are legally separate entities but operationally aligned through Chase's leadership of both efforts.

No. The firm uses deal-by-deal capital formation rather than a blind-pool fund structure, and it targets permanent-hold ownership rather than a 5-to-7-year liquidation timeline. Dave Chase has described this as closer to a holding-company or Berkshire-style model than to conventional private equity, which appeals to family offices and operators seeking long-duration healthcare exposure.

The firm focuses on US-based middle-market healthcare-services companies with $5 million to $50 million in revenue and demonstrated profitability. Target sub-sectors include revenue-cycle management, third-party benefits administration, and tech-enabled care delivery. The firm looks for founder-owned businesses that need operational scaling rather than financial restructuring.

The Health Rosetta certification framework provides a unique deal-sourcing channel by identifying companies that already align with the Rosetta standard or could be made to align post-acquisition. The nonprofit's public ecosystem of employers, advisors, and service providers also generates referrals, while Chase's conference appearances and published writing on healthcare purchasing failures create inbound founder inquiries.